163 related articles for article (PubMed ID: 25369606)
1. Angiopoietins in haematopoietic stem cell mobilisation in patients with haematological malignancies.
Szmigielska-Kaplon A; Krawczynska A; Czemerska M; Pluta A; Cebula-Obrzut B; Szmigielska K; Stępka K; Smolewski P; Robak T; Wierzbowska A
Blood Transfus; 2015 Jan; 13(1):102-8. PubMed ID: 25369606
[TBL] [Abstract][Full Text] [Related]
2. The kinetics of hematopoietic niche cytokines and their influence on mobilization efficacy and timing in patients with hematological malignancies.
Szmigielska-Kaplon A; Krawczynska A; Czemerska M; Pluta A; Cebula-Obrzut B; Robak M; Grzybowska-Izydorczyk O; Szmigielska K; Robak T; Wierzbowska A
J Clin Apher; 2015 Aug; 30(4):247-51. PubMed ID: 25352518
[TBL] [Abstract][Full Text] [Related]
3. Haematological recovery in poor and good haematopoietic stem cell mobilisers.
De Santis GC; Garcia-Silva AC; Chiaramonte NC; Orellana MD; Prado BP; Oliveira LC; Simões BP; Covas DT
Transfus Med; 2016 Aug; 26(4):297-300. PubMed ID: 27237104
[TBL] [Abstract][Full Text] [Related]
4. Changes in vascular endothelial growth factor, angiopoietins, and Tie-2 levels with G-CSF stimulation in healthy donors.
Serefhanoglu S; Goker H; Buyukasik Y; Turgut M; Sayinalp N; Haznedaroglu IC; Aksu S; Akman U; Ozcebe OI
Ann Hematol; 2009 Jul; 88(7):667-71. PubMed ID: 19082594
[TBL] [Abstract][Full Text] [Related]
5. Early total white blood cell recovery is a predictor of low number of apheresis and good CD34(+) cell yield.
Marques JF; Vigorito AC; Aranha FJ; Lorand-Metze I; Miranda EC; Lima Filho EC; Valbonesi M; Santini G; De Souza CA
Transfus Sci; 2000 Oct; 23(2):91-100. PubMed ID: 11035269
[TBL] [Abstract][Full Text] [Related]
6. Polymorphism of CD44 influences the efficacy of CD34(+) cells mobilization in patients with hematological malignancies.
Szmigielska-Kaplon A; Szemraj J; Hamara K; Robak M; Wolska A; Pluta A; Czemerska M; Krawczynska A; Jamroziak K; Szmigielska K; Robak T; Wierzbowska A
Biol Blood Marrow Transplant; 2014 Jul; 20(7):986-91. PubMed ID: 24680978
[TBL] [Abstract][Full Text] [Related]
7. VEGF, ANGPT1, ANGPT2, and MMP-9 expression in the autologous hematopoietic stem cell transplantation and its impact on the time to engraftment.
Nowicki M; Wierzbowska A; Małachowski R; Robak T; Grzybowska-Izydorczyk O; Pluta A; Szmigielska-Kapłon A
Ann Hematol; 2017 Dec; 96(12):2103-2112. PubMed ID: 28956132
[TBL] [Abstract][Full Text] [Related]
8. Predictors of poor haematopoietic stem cell mobilisation in patients with haematological malignancies at a South African centre.
du Toit J; Goeijenbier M; du Toit C; de Witt P; Koornhof H; Oosthuizen J; Louw VJ; Seftel M; Verburgh E
Transfus Apher Sci; 2022 Aug; 61(4):103419. PubMed ID: 35288051
[TBL] [Abstract][Full Text] [Related]
9. A randomized clinical trial comparing granulocyte-colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation.
Renfroe H; Arnold M; Vaughn L; Harvey RD; Hamilton E; Lonial S; Khoury HJ; Kaufman JL; Lechowicz MJ; Flowers CR; Waller EK
Transfusion; 2011 Aug; 51(8):1779-83. PubMed ID: 21332729
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo expansion of megakaryocyte progenitor cells from normal bone marrow and peripheral blood and from patients with haematological malignancies.
Blair A; Baker CL; Pamphilon DH; Judson PA
Br J Haematol; 2002 Mar; 116(4):912-9. PubMed ID: 11886401
[TBL] [Abstract][Full Text] [Related]
11. Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents.
Terpos E; Anargyrou K; Katodritou E; Kastritis E; Papatheodorou A; Christoulas D; Pouli A; Michalis E; Delimpasi S; Gkotzamanidou M; Nikitas N; Koumoustiotis V; Margaritis D; Tsionos K; Stefanoudaki E; Meletis J; Zervas K; Dimopoulos MA;
Int J Cancer; 2012 Feb; 130(3):735-42. PubMed ID: 21484787
[TBL] [Abstract][Full Text] [Related]
12. Impact of chemotherapy on the mobilisation, harvest and economic costs of autologous peripheral stem cell transplantation in patients with multiple myeloma.
Jerjis S; Croockewit S; Preijers F; Schaap N; De Witte T
Leuk Lymphoma; 2000 May; 37(5-6):551-60. PubMed ID: 11042515
[TBL] [Abstract][Full Text] [Related]
13. CD34+ enriched cell products intended for autologous transendocardial CD34+ cell transplantation release significant amounts of angiopoietin-1.
Rozman JZ; Jez M; Malicev E; Krasna M; Vrtovec B; Cukjati M; Rozman P
Transfus Clin Biol; 2019 Nov; 26(4):273-278. PubMed ID: 30709720
[TBL] [Abstract][Full Text] [Related]
14. Circulating endothelial cell kinetics and their potential predictive value during mobilization procedure.
Szmigielska-Kapłon A; Krawczyńska A; Czemerska M; Pluta A; Cebula-Obrzut B; Szmigielska K; Smolewski P; Robak T; Wierzbowska A
J Clin Apher; 2013 Oct; 28(5):341-8. PubMed ID: 23681977
[TBL] [Abstract][Full Text] [Related]
15. Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma.
Micallef IN; Apostolidis J; Rohatiner AZ; Wiggins C; Crawley CR; Foran JM; Leonhardt M; Bradburn M; Okukenu E; Salam A; Matthews J; Cavenagh JD; Gupta RK; Lister TA
Hematol J; 2000; 1(6):367-73. PubMed ID: 11920216
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Hematopoietic Stem Cell Mobilization Rates with Early Plerixafor Administration for Adult Stem Cell Transplantation.
Stover JT; Shaw JR; Kuchibhatla M; Horwitz ME; Engemann AM
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1290-1294. PubMed ID: 28411174
[TBL] [Abstract][Full Text] [Related]
17. Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.
Russell N; Douglas K; Ho AD; Mohty M; Carlson K; Ossenkoppele GJ; Milone G; Pareja MO; Shaheen D; Willemsen A; Whitaker N; Chabannon C
Haematologica; 2013 Feb; 98(2):172-8. PubMed ID: 22983579
[TBL] [Abstract][Full Text] [Related]
18. Stable colony-stimulating factor 1 fusion protein treatment increases hematopoietic stem cell pool and enhances their mobilisation in mice.
Kaur S; Sehgal A; Wu AC; Millard SM; Batoon L; Sandrock CJ; Ferrari-Cestari M; Levesque JP; Hume DA; Raggatt LJ; Pettit AR
J Hematol Oncol; 2021 Jan; 14(1):3. PubMed ID: 33402221
[TBL] [Abstract][Full Text] [Related]
19. Angiopoietin-2: a potential novel diagnostic marker in multiple myeloma.
Joshi S; Khan R; Sharma M; Kumar L; Sharma A
Clin Biochem; 2011 Jun; 44(8-9):590-5. PubMed ID: 21300047
[TBL] [Abstract][Full Text] [Related]
20. A clinical comparison of the efficacy and safety of biosimilar G-CSF and originator G-CSF in haematopoietic stem cell mobilization.
Manko J; Walter-Croneck A; Jawniak D; Grzasko N; Gorska-Kosicka M; Cioch M; Dmoszynska A
Pharmacol Rep; 2014 Apr; 66(2):239-42. PubMed ID: 24911076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
